São Paulo - Delayed Quote BRL

Hypera S.A. (HYPE3.SA)

24.92
+0.23
+(0.93%)
At close: May 16 at 5:07:42 PM GMT-3
Loading Chart for HYPE3.SA
  • Previous Close 24.69
  • Open 0.00
  • Bid 24.77 x --
  • Ask 25.20 x --
  • Day's Range 0.00 - 0.00
  • 52 Week Range 0.00 - 32.36
  • Volume 0
  • Avg. Volume 5,191,196
  • Market Cap (intraday) 15.772B
  • Beta (5Y Monthly) 0.36
  • PE Ratio (TTM) 19.62
  • EPS (TTM) 1.27
  • Earnings Date Aug 7, 2025
  • Forward Dividend & Yield 1.17 (4.69%)
  • Ex-Dividend Date Mar 28, 2025
  • 1y Target Est 25.77

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex – A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, Equilibrisse, balance, Flavonid, Histamin, neofresh, neolefrin, neoquimica Vitamins, Neosorum, and Torsilax brands; and over-the-counter drugs under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Biotônico Fontoura, and Zero-Cal brands; and generic medicines under the Hydroxyzine, Sodium Diclofenac, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brands. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 1999 and is headquartered in São Paulo, Brazil.

www.hypera.com.br

10,481

Full Time Employees

December 31

Fiscal Year Ends

Recent News: HYPE3.SA

View More

Performance Overview: HYPE3.SA

Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is IBOVESPA (^BVSP) .

YTD Return

HYPE3.SA
39.83%
IBOVESPA (^BVSP)
15.72%

1-Year Return

HYPE3.SA
13.61%
IBOVESPA (^BVSP)
8.50%

3-Year Return

HYPE3.SA
24.87%
IBOVESPA (^BVSP)
28.60%

5-Year Return

HYPE3.SA
5.53%
IBOVESPA (^BVSP)
79.46%

Compare To: HYPE3.SA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: HYPE3.SA

View More

Valuation Measures

Annual
As of 5/16/2025
  • Market Cap

    15.77B

  • Enterprise Value

    23.34B

  • Trailing P/E

    19.64

  • Forward P/E

    14.31

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.37

  • Price/Book (mrq)

    1.34

  • Enterprise Value/Revenue

    3.49

  • Enterprise Value/EBITDA

    16.38

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    12.08%

  • Return on Assets (ttm)

    2.56%

  • Return on Equity (ttm)

    6.84%

  • Revenue (ttm)

    6.7B

  • Net Income Avi to Common (ttm)

    810.61M

  • Diluted EPS (ttm)

    1.27

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.74B

  • Total Debt/Equity (mrq)

    81.27%

  • Levered Free Cash Flow (ttm)

    1.25B

Research Analysis: HYPE3.SA

View More

Company Insights: HYPE3.SA

Research Reports: HYPE3.SA

View More

People Also Watch